Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism - A Predetermined Companion Report From the ONCO PE Trial
BACKGROUND: Patients with appropriately selected low-risk pulmonary embolism (PE) can be treated at home, although it has been controversial whether applies to patients with cancer, who are considered not to be at low risk.Methods and Results: The current predetermined companion report from the ONCO PE trial evaluated the 3-month clinical outcomes of patients with home treatment and those with in-hospital treatment. The ONCO PE trial was a multicenter, randomized clinical trial among 32 institutions in Japan investigating the optimal duration of rivaroxaban treatment in cancer-associated PE patients with a score of 1 using the simplified version of the Pulmonary Embolism Severity Index (sPESI). Among 178 study patients, there were 66 (37%) in the home treatment group and 112 (63%) in the in-hospital treatment group. The primary endpoint of a composite of PE-related death, recurrent venous thromboembolism (VTE) and major bleeding occurred in 3 patients (4.6% [0.0-9.6%]) in the home treatment group and in 2 patients (1.8% [0.0-4.3%]) in the in-hospital treatment group. In the home treatment group, there were no cases of PE-related death or recurrent VTE, but major bleeding occurred in 3 patients (4.6% [0.0-9.6%]), and 2 patients (3.0% [0.0-7.2%]) required hospitalization due to bleeding events.
CONCLUSIONS: Active cancer patients with PE of sPESI score=1 could be potential candidates for home treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Circulation journal : official journal of the Japanese Circulation Society - (2024) vom: 08. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chatani, Ryuki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Revised 10.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1253/circj.CJ-24-0004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369522656 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369522656 | ||
| 003 | DE-627 | ||
| 005 | 20240311232911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1253/circj.CJ-24-0004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM369522656 | ||
| 035 | |a (NLM)38462535 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chatani, Ryuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism - A Predetermined Companion Report From the ONCO PE Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a BACKGROUND: Patients with appropriately selected low-risk pulmonary embolism (PE) can be treated at home, although it has been controversial whether applies to patients with cancer, who are considered not to be at low risk.Methods and Results: The current predetermined companion report from the ONCO PE trial evaluated the 3-month clinical outcomes of patients with home treatment and those with in-hospital treatment. The ONCO PE trial was a multicenter, randomized clinical trial among 32 institutions in Japan investigating the optimal duration of rivaroxaban treatment in cancer-associated PE patients with a score of 1 using the simplified version of the Pulmonary Embolism Severity Index (sPESI). Among 178 study patients, there were 66 (37%) in the home treatment group and 112 (63%) in the in-hospital treatment group. The primary endpoint of a composite of PE-related death, recurrent venous thromboembolism (VTE) and major bleeding occurred in 3 patients (4.6% [0.0-9.6%]) in the home treatment group and in 2 patients (1.8% [0.0-4.3%]) in the in-hospital treatment group. In the home treatment group, there were no cases of PE-related death or recurrent VTE, but major bleeding occurred in 3 patients (4.6% [0.0-9.6%]), and 2 patients (3.0% [0.0-7.2%]) required hospitalization due to bleeding events | ||
| 520 | |a CONCLUSIONS: Active cancer patients with PE of sPESI score=1 could be potential candidates for home treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticoagulants | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Cardio-oncology | |
| 650 | 4 | |a Home treatment | |
| 650 | 4 | |a Pulmonary embolism | |
| 700 | 1 | |a Yamashita, Yugo |e verfasserin |4 aut | |
| 700 | 1 | |a Morimoto, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Muraoka, Nao |e verfasserin |4 aut | |
| 700 | 1 | |a Shioyama, Wataru |e verfasserin |4 aut | |
| 700 | 1 | |a Shibata, Tatsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimoto, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Ogihara, Yoshito |e verfasserin |4 aut | |
| 700 | 1 | |a Doi, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Oi, Maki |e verfasserin |4 aut | |
| 700 | 1 | |a Shiga, Taro |e verfasserin |4 aut | |
| 700 | 1 | |a Sueta, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Kitae |e verfasserin |4 aut | |
| 700 | 1 | |a Tanabe, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Koitabashi, Norimichi |e verfasserin |4 aut | |
| 700 | 1 | |a Takada, Takuma |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakagawa, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Mitsuhashi, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Shoji, Masaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Sakamoto, Jiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hisatake, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Ogino, Yutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Fujita, Masashi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakanishi, Naohiko |e verfasserin |4 aut | |
| 700 | 1 | |a Dohke, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hiramori, Seiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Nawada, Ryuzo |e verfasserin |4 aut | |
| 700 | 1 | |a Kaneda, Kazuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Mushiake, Kazunori |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Hiromi |e verfasserin |4 aut | |
| 700 | 1 | |a Kadota, Kazushige |e verfasserin |4 aut | |
| 700 | 1 | |a Ono, Koh |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Takeshi |e verfasserin |4 aut | |
| 700 | 0 | |a ONCO PE Trial Investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation journal : official journal of the Japanese Circulation Society |d 2002 |g (2024) vom: 08. März |w (DE-627)NLM118044850 |x 1347-4820 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:08 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1253/circj.CJ-24-0004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 08 |c 03 | ||